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Summary
OBJECTIVE: Whether underlying chronic respiratory dis-
eases are susceptible factors for symptomatic episodes,
which lead to primary-level care, in association with air
pollutant exposures is unknown. We evaluated and com-
pared association lag structures between daily ambient
levels of nitrogen dioxide (NO2) and total suspended par-
ticulates (TSP) and respiratory symptom-related doctor vis-
its in adults with different patterns of underlying chronic
respiratory disease.
METHODS: In a time-stratified case-crossover analysis
nested within a diary panel study, 459 Swiss adult parti-
cipants with asthma, chronic bronchitis, chronic obstruct-
ive pulmonary disease (COPD) and healthy participants re-
corded occurrence of respiratory-symptom related doctor
visits (n = 1,048) in one to six four-week intervals over
two years. For each disease subgroup, odds ratios (ORs)
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for doctor visit were estimated as a function of NO2 or
TSP concentrations (per 10 micrograms per cubic meter
[µg/m3]) lagged between 0–13 days in a polynomial dis-
tributed lag model.
RESULTS: Higher ORs for NO2 in participants with COPD
(OR: 1.17, 95%CI: 1.02–1.35) and asthma (OR: 1.15,
95%CI: 1.02–1.30) occurred at exposure lags of two and
five days, respectively. Doctor visits increased by 9.1%
(95%CI: 3.2–15.4%) and 4.2% (95%CI: 1.2–7.2%) over
the first week following a 10 µg/m3 increase in NO2 con-
centration in the COPD and chronic bronchitis subgroups,
respectively. The percent increase in the COPD subgroup
was significantly greater (p <0.05) when compared with the
healthy subgroup. Observed findings were similar for TSP.
CONCLUSIONS: Respiratory problems leading to a doc-
tor visit, associated with an increase in exposure to NO2
and TSP, may have a faster dynamic in individuals with
COPD.
Key words: air pollution; respiratory symptoms; disease
susceptibility; asthma; COPD
Introduction
The effect of air pollution on respiratory morbidity and
mortality in adults is well documented in epidemiologic
studies which examine severe outcomes including emer-
gency room visits or hospitalisations. There is also evid-
ence to suggest that individuals with underlying chronic
respiratory disease including asthma or chronic obstructive
pulmonary disease (COPD) are more susceptible to the
acute effects of air pollutants including aggravation of res-
piratory symptoms, hospitalisations, and mortality [1–4].
Less is known about the effect of air pollution on respir-
atory outcomes in the context of a primary healthcare set-
ting, such as visits to the doctor for general consultation or
doctors’ house calls in relation to respiratory symptoms or
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disease [5–8]. Symptomatic respiratory episodes leading to
subsequent primary care are likely to be less severe than
those that lead to emergency care, but they may also be
more common, resulting in time off from work for the doc-
tor visit or for home recuperation, suggesting a large im-
pact in terms of public health and societal costs. Doctor vis-
its may serve as a useful indicator for the health effects of
air pollution in the acute time domain. Whether adults with
underlying chronic respiratory diseases are more suscept-
ible to respiratory symptom-related doctor visits in associ-
ation with air pollutant exposure is unknown.
The purpose of this study was to investigate the effects of
current levels of ambient nitrogen dioxide (NO2) and total
suspended particulates (TSP), as markers of traffic-related
particulate matter, on doctor visits for respiratory problems
in a large diary panel study of adults that was conduc-
ted in 1992 and 1993 as part of the Swiss Cohort Study
on Air Pollution and Lung and Heart Diseases in Adults
(SAPALDIA). While the data from the SAPALDIA diary
study was collected nearly 20 years ago, the size of the
diary panel study is unprecedented, and the time patterns
of exposure-response over a long duration have not been
addressed in the literature. Furthermore, while air qual-
ity in Switzerland may have changed over time, air qual-
ity in Switzerland from the early 1990’s is still a reason-
able proxy of air quality in many other places in the world.
Many of the diary study participants were also present with
symptoms consistent with asthma, chronic bronchitis, and
COPD, thus providing a unique opportunity to evaluate as-
sociation lag structures in short-term effects of air pollutant
levels related to primary care in adults with different pat-
terns of underlying chronic disease.
Methods
Study population and design
SAPALDIA is a multicenter and population based pro-
spective cohort study consisting of a random sample of
9,561 adults between the ages of 18–60 recruited from
eight regions (Aarau, Basel, Davos, Geneva, Lugano,
Montana, Payerne, and Wald) in Switzerland. Baseline ex-
amination occurred in 1991 where participants were ad-
ministered a detailed respiratory health questionnaire and
underwent allergy, lung function, and methacholine chal-
lenge testing [9, 10]. A subset of the study population at
baseline (n = 5,383) was invited to enrol in a longitudinal
diary study spanning 1992 and 1993 [11, 12]. Participants
with a higher probability of reporting respiratory symptoms
in the baseline survey were over-sampled for inclusion in
the diary study to enhance the study's statistical power to
detect associations between air pollution and lung diseases.
Accordingly, meeting one of the following criteria assessed
in the baseline survey was sufficient for a subject to be eli-
gible for participation in the diary study: (1.) an affirmative
answer to at least one of a set of 10 questions on respiratory
symptoms; (2.) a ratio between forced expiratory volume
in 1 second (FEV1) and forced vital capacity that was less
than 80% of the value predicted by European Community
Coal and Steel norms; (3.) a decline in FEV1, of at least
20% from baseline during the bronchochallenge test; and
(4.) satisfying none of the above criteria and being a non-
smoker. All participants fulfilling at least one of the first
three criteria at the baseline survey were invited to enroll
in the diary study. Participants fulfilling the fourth criterion
were restricted to a random sample of 150 non-symptomat-
ic non-smokers per area [11]. Of the 5,383 individuals in-
vited to enrol, 3,279 participated (60.9%) [11, 12]. Ethical
approval for this study was given by the ethics committees
of the participating cantons in each study region.
The diary study participants completed up to 6 diary peri-
ods of 4 weeks in duration, in 1992 and 1993, during which
they recorded daily occurrence of respiratory symptoms
and visits to the doctor for respiratory symptoms. Of the
3,279 diary study participants, we included the 459 indi-
viduals in this analysis who reported at least one doctor vis-
it for a total of 1,048 visits. A time-stratified case-crossov-
er analysis was developed, where for each participant a day
with a reported doctor visit (case-day) was matched with
all days absent of a doctor visit (control-day) that occurred
in the diary period by weekday [13]. Case and control-days
were excluded from the analysis if the participant did not
report being present in the study area on that day. For this
analysis, there was complete information on NO2 exposure
and other covariates in 914 case-days (i.e., reported doc-
tor visits) and 2,362 control-days; for TSP, there were 892
case-days and 2,230 control-days with complete informa-
tion.
Definition of subgroups
Of the 459 participants, 374 were divided into subgroups
of having asthma (n = 78), chronic bronchitis (n = 189) or
COPD (n = 54), or who were healthy (n = 116). Presence of
asthma was derived from positive responses to the follow-
ing questions, “Have you ever had asthma?’’ and ‘‘was this
confirmed by a doctor?’’. Chronic bronchitis was defined
as self-report of cough or phlegm during the day or at
night on most days for as much as 3 months each year
for ≥2 years. COPD was defined as a ratio of forced ex-
piratory volume in 1 second over forced vital capacity
(FEV1/FVC) less than 70% and no previous history of
asthma or current asthma medication use. Thus, while par-
ticipants overlapped between the asthma and chronic bron-
chitis subgroups, the asthma and COPD subgroups were
mutually exclusive. For this analysis, participants were
defined as healthy if they did not meet the criteria for in-
clusion for asthma, chronic bronchitis, or COPD and if
they were not present with bronchial hyper-responsiveness
at the baseline survey; 14 of the 116 participants in the
healthy subgroup were current smokers.
Definition of doctor visit for respiratory symptoms
Doctor visits for respiratory symptoms were divided into
two subcategories: lower respiratory symptoms (wheezing
or tightness of chest or trouble breathing or cough or
phlegm during the day or the preceding night), and upper
respiratory symptoms (sore throat or hoarseness or runny
nose during the day or the preceding night and no lower
respiratory symptoms).
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Air pollution exposure assessment
Additional details on exposure measurements are provided
in Monn et al. [14]. NO2 and TSP were monitored at fixed
sites by local authorities in the eight SAPALDIA regions,
and 24-hour means of NO2 (µg/m3) and half-hourly means
of TSP (µg/m3) were used in this analysis. Particulate mat-
ter of 2.5 nor 10 micrometers in diameter (PM2.5 and PM10,
respectively) were not monitored on a daily basis at the
time of the diary study, but a previous exposure assessment
study demonstrated a high correlation between weekly av-
erages of TSP and PM10 in the SAPALDIA regions [15].
In the same study, a high correlation was also observed
between PM10 and NO2 in the urban regions. At the time
of the diary study, emission sources for NO2 in Switzerland
were predominately automobile traffic [15, 16].
Meteorological parameters including 24-hour means of
temperature (T), relative humidity (RH), and atmospheric
pressure (AP), were also collected for each SAPALDIA re-
gion. For chronological gaps of ≤2 consecutive days in the
diary period with missing data for NO2, TSP, T, RH, or
AP, linear interpolation between the day before and the day
after was used to impute the missing data. Of the 3,276
person-days of observation with complete information spe-
cific to the NO2 analysis, 465 person-days consisted of im-
puted pollutant or meteorological data; 356 of the 3,122
person-days specific to the TSP analysis consisted of im-
puted pollutant or meteorological data.
Statistical analysis
Conditional logistic regression (CLR), performed with the
PROC PHREG procedure in SAS V 9.2 (SAS Institute,
Cary, NC, 2008), was used to estimate odds ratios (OR)
and 95% confidence intervals for doctor visits for respirat-
ory symptoms (combination of upper and lower respiratory
symptoms) as a function of NO2 or TSP concentration (per
10 µg/m3) in a polynomial distributed lag model. The poly-
nomial distributed lag model was derived from NO2 and
TSP concentrations on the respective case or control-day of
observation and the previous 13 days to account for sub-
stantial correlation between air pollution concentrations on
days close together [17, 18], including terms up to the 5th
degree order constrained in such a way that the resulting
function had linear tails between lags 0 and 1 and between
lags 12 and 13. Longer lag structures up to two weeks were
also developed in this analysis to enhance stability of the
distributed lag estimates, and because the previous literat-
ure demonstrates that lags beyond one week have some in-
fluence on respiratory mortality and morbidity [19, 20].
All models were adjusted for time-varying covariates in-
cluding quadratic polynomial distributed lag function of T,
RH, AP, T2, RH2, and RH*T on the respective day and the
6 preceding days (i.e., lag 0 to 6) up to ≤2 degrees for each
term, and average T, RH, and AP from lag 7 to lag 13 days.
Finally, there was additional adjustment for weekly aver-
age influenza incidence at the regional level, which was
provided by the Federal Office of Public Health. All mod-
els were stratified by gender and smoking status (current
smoker, former or never smoker); there was insufficient
power to distinguish the effect of exposure between former
and never smokers, particularly in the COPD subgroup, so
we chose to combine former and never smokers. Doctor
visits were also limited to lower respiratory symptoms in a
secondary analysis.
For each subgroup, the average percent change in doctor
visits for respiratory symptoms was estimated over 1 or 2
weeks following a 10 µg/m3 increase in NO2 and TSP con-
centration on a given day by computing the area under the
curve (AUC), which was derived from summing logits lag
0 to 6 or lag 0 to 13 days from the CLR models and then
exponentiating their sum. The difference in AUC between
mutually exclusive subgroups was estimated to evaluate
whether time patterns were distinguishable between the
subgroups.
Results
Different patterns of characteristics emerged between the
subgroups as shown in table 1. Participants with COPD
were more likely to be male, considerably older, report
more than one doctor visit, and be a current smoker com-
pared with participants with asthma and healthy parti-
cipants. The majority of doctor visits were for lower rather
Figure 1
Adjusted OR’s* for doctor’s visit for respiratory symptoms per
10 µg/m3 increase in NO2.
* As estimated in separate conditional logistic regression models in
the asthma, chronic bronchitis, COPD, and healthy subgroups, and
adjusted for flu prevalence, polynomial distributed lags of T, RH, AP,
T2, RH2, and T*RH from lag 0–6 days at up to 2 degrees of
freedom, and average T, RH, AP, and T2 from lag 7–13 days.
Figure 2
Average percent change* in number of doctor visits following a
10 µg/m3 increase in NO2 concentration.
* For each subgroup, areas under the curve were estimated from
adjusted conditional logistic regression models to approximate the
average percent change in number of doctor visits over 1 and
2 week periods following a 10 µg/m3 increase in exposure to NO2
concentration on a given day.
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than upper respiratory symptoms, but healthy participants
had the highest proportion of doctor visits for upper respir-
atory symptoms.
Comparison of characteristics at the baseline SAPALDIA
survey between participants who reported or did not report
doctor visits was also evaluated within the asthma and
COPD subgroups (supplementary file table 1). Among par-
ticipants with COPD, the distributions of age, current
smoking status, symptoms consistent with chronic bron-
chitis, and percent predicted FEV1 were not considerably
different between those who reported and did not report
doctor visits. Asthmatics who reported doctor visits had
significantly lower percent predicted forced expiratory
volume in one second (FEV1) and a significantly higher
prevalence of self-reported asthma medication use.
NO2 and doctor visits
The mean NO2 concentration observed on case and control-
days, and the differences between them from the same risk
set are summarised in table 2. On average, higher NO2 con-
centrations were observed on case-days relative to control-
days (i.e., at an exposure lag of 0 days). From an exposure
lag of 1 day onward, the difference in NO2 concentration,
relative to control-days, continued to rise and peaked at an
exposure lag of 4 days, before trending downward into neg-
ative territory by a lag of 8 days. A high correlation was ob-
served between NO2 and TSP concentrations (Pearson cor-
relation r2 = 0.72) at exposure lag of 0 days.
The maximum OR for a doctor visit related to respiratory
symptoms per 10 µg/m3 increase in NO2 in all participants
occurred at an exposure lag of 4 days (OR: 1.038, 95%CI:
0.999–1.077), indicating a small increase in doctor visits.
A bimodal lag distribution of peak effects of NO2 occurred
in all subgroups, but the timing and strength of the peak
effects varied by condition (fig. 1, table 3). In the asthma
subgroup, the peak effects occurred at exposure lags of 5
and 13 days, but at shorter lags for participants with chron-
ic bronchitis and COPD, all of which were statistically sig-
nificant (p <0.05). In the healthy subgroup, the peak effects
occurred at exposure lags of 5 and 10 days. Statistically
significant inverse associations were also observed in the
healthy and chronic bronchitis subgroups at lags of 2 and
9 days, respectively. Exposure lag patterns were broadly
similar when doctor visits were limited to lower respiratory
symptoms (data not shown).
Transformation of the AUC’s from the CLR models into
average percent changes in doctor visits following an in-
crease NO2 exposure is illustrated in figure 2. The largest
increase in doctor visits was observed in the COPD sub-
group; a 10 µg/m3 increase in NO2 concentration on a
given day was associated with a 9.1% increase (95%CI:
3.2–15.4%) in doctor visits for respiratory symptoms on
average over the first week following exposure. The in-
crease in doctor visits for the COPD subgroup was reduced
to 4.4% over two weeks following exposure, but remained
statistically significant (95%CI: 0.6–8.3%). Average in-
creases in doctor visits in both time periods were also ob-
served in the asthma and chronic bronchitis subgroups, but
were only statistically significant for those with chronic
bronchitis over one week following an increase in exposure
(4.2%, 95%CI: 1.2–7.2%). Average decreases in doctor
visits were observed in the healthy subgroup for both time
periods, but these changes were not statistically significant.
The differences in average change in doctor visits were
statistically significant in both time periods between the
COPD and healthy subgroups, and over the first week
between the COPD and asthma subgroups.
The peak effects of NO2 occurring with shorter exposure
lags in the COPD subgroup, as shown in figures 1 and
2, were largely observed in current smokers (supplement-
ary file table 2). There was little difference in effect lag
patterns observed between current and non-smokers with
chronic bronchitis. For participants with asthma, the peak
effects of NO2 in both groups occurred at exposure lags of
approximately 5–6 days and 13 days.
Differences in exposure lag patterns by gender also varied
between subgroups (supplementary file table 3). In the
COPD subgroup, the peak effects of NO2 occurred at ex-
posure lags between 0 and 3 days in females and between
2 and 4 days in males. For the chronic bronchitis subgroup,
elevated ORs were observed mainly in males at exposure
lags between 0 and 1 days and between 4 and 6 days. Ex-
posure lag patterns were similar between males and fe-
males with asthma.
TSP and doctor visits
The results for TSP and doctor visits (see supplementary
file) were broadly similar to those observed for NO2. The
adjusted OR for doctor visits in all subjects was highest
at an exposure lag of 4 days (OR: 1.038, 95%CI:
1.010–1.065). In comparison with the asthma and healthy
subgroups, the peak effect of TSP occurred at a shorter
exposure lag in the COPD subgroup (supplementary file
fig. 1A–1D, table 5), and the effect was largely apparent in
smokers and females of this subgroup (supplementary file
tables 6 and 7).
Discussion
We observed positive associations between ambient ex-
posures to NO2 and visits to the doctor for respiratory
symptoms on days following exposure, but the timing and
magnitude in the effect of NO2 varied by the underlying
respiratory condition. Participants in the COPD subgroup
were more vulnerable during the first week following an
increase in exposure to NO2 compared with those in the
asthma and healthy subgroups. The results for TSP were
broadly similar to those observed for NO2.
Few studies have examined effects of ambient air pollut-
ants on respiratory morbidity outcomes in adults in primary
care rather than emergency care settings. Previous studies
of air pollution and general practice consultations for
asthma or lower respiratory tract diseases in London [5],
and doctors’ house calls for upper or lower respiratory tract
diseases in the greater Paris area [4] observed no significant
associations with NO2. The former study did not consider
exposure lags more than 3 days, but the latter study evalu-
ated up to 15 days and also found that the effects of PM10
on house calls for lower respiratory diseases persisted until
4 days after exposure followed by a steady decrease.
The studies cited in the previous paragraph did not evaluate
the susceptibility to respiratory health effects of air pollut-
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ants by pre-existing chronic respiratory disease. There is
evidence from both epidemiologic and laboratory studies
to suggest that adults with asthma and COPD are particu-
larly sensitive to air pollutants using a wide range of out-
comes that include aggravation of respiratory symptoms,
emergency room visits, and hospital admissions [1, 2, 21,
22]. Evaluation of susceptibility factors may also help re-
define exposure limits. The findings from our study indic-
ate that the number of doctor visits for respiratory symp-
toms among individuals with COPD would increase by
9.1% over the course of one week following an increase of
10 µg/m3 of exposure to NO2. COPD is a common disease
in most countries, with a reported prevalence in Europe
and United States falling between 4 and 10% [23]. Thus,
the present findings re-emphasise that air quality improve-
ments would represent considerable medical and other so-
cietal savings, and should be included in general strategies
for disease prevention [24].
The variation in lag distribution of effects between the dis-
ease subgroups is also of particular interest. The observed
findings suggest that the time to doctor visit following in-
crease in exposure to NO2 is more immediate for indi-
viduals who have at least mild COPD than for those with
asthma. Both diseases are characterised by chronic inflam-
matory processes, but the general features are distinct with
different pathophysiology. Airflow obstruction is poorly re-
versible for COPD in comparison with asthma, whose ex-
acerbations can be managed more effectively with the use
of bronchodilators and inhaled steroids. Thus, the vari-
ation in lag distribution of effects may reflect a comparison
of disease severity between COPD and asthma. However,
there may be alternative explanations for the observed find-
ings. First, differences in lag time and associations with
doctor visits observed between the subgroups may be at-
tributable to differences in smoking and gender. Lagged ef-
fect patterns of NO2 exposure were similar for asthma and
COPD when the analysis was limited to former and never
smokers, but the effects were more immediate and higher
for COPD than asthma in current smokers. Although it is
known that there are gender differences in treatment seek-
ing behaviour, the lagged effects of NO2 exposure on doc-
tor visits were more immediate for COPD than for asthma
in both males and females. Secondly, peak effects may
have occurred at shorter exposure lags for participants with
COPD and chronic bronchitis because they are less likely
to take medication compared with participants with asthma.
It is possible that the use of bronchodilators or inhaled ster-
oids in asthma exacerbations may delay (or postpone) the
decision to visit the doctor. However, effects of NO2 expos-
ure did not differ considerably between asthmatics who re-
ported use of asthma medication in the 1991 baseline sur-
vey and those who did not (data not shown). Molecular and
genetic epidemiology may help to elucidate the biological
mechanisms of susceptibility to respiratory health effects in
Table 1: Characteristics of participants who reported doctor visits for respiratory symptoms in the SAPALDIA diary study.
Participants with at least one visit to the doctor
Characteristics Asthma Bronchitis COPD Healthy
Number of subjects 78 189 54 116
n (%)* n (%) n (%) n (%)
Sex
Male 31 (39.7) 81 (42.9) 29 (53.7) 34 (29.3)
Female 47 (60.3) 108 (57.1) 25 (46.3) 82 (70.7)
Age
<35 17 (21.8) 39 (20.6) 7 (13.0) 33 (28.5)
35–45 24 (30.8) 50 (26.5) 10 (18.5) 41 (35.3)
>45 37 (47.4) 100 (52.9) 37 (68.5) 42 (36.2)
mean (SD) 43.6 (10.1) 44.3 (9.9) 48.2 (9.9) 41.5 (10.2)
Smoking status
Current smoker 14 (17.3) 80 (42.3) 24 (46.0) 14 (10.4)
Former smoker 24 (30.8) 37 (19.6) 13 (24.1) 29 (25.0)
Never smoker 40 (51.3) 72 (38.1) 17 (31.5) 73 (63.0)
Medication**
Current use of asthma medication 35 (44.9) 22 (11.6) 0 0
Use of inhalation steroids in last 12 months 18 (23.1) 12 (6.4) 0 0
Lung function
Percent predicted FEV1, mean (SD) 88.9 (21.9) 100.2 (20.3) 91.9 (16.2) 112.1 (13.7)
FEV1/FVC, %, mean (SD) 71.7 (11.8) 75.5 (10.3) 63.4 (6.2) 81.3 (5.6)
PEF***, %, mean (SD) 6.77 (2.33) 7.04 (2.46) 6.47 (2.55) 7.63 (2.40)
Visits to the doctor
1 43 (55.1) 95 (50.3) 24 (44.4) 65 (56.0)
>1 35 (44.9) 94 (49.7) 30 (55.6) 51 (44.0)
Visits to the doctor
Type Asthma Bronchitis COPD Healthy
All visits 201 478 166 231
Visits for upper respiratory symptoms 20 63 42 86
Visits for lower respiratory symptoms 181 415 124 145
* Summarised in n (%) unless noted otherwise.
** Self-reported medication use ascertained from SAPALDIA 1 survey (1991).
*** Peak expiratory flow variability expressed as amplitude as a percent of mean.
Original article Swiss Med Wkly. 2012;142:w13681
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 17
air pollution, which has important links with systemic in-
flammation and oxidative stress, in individuals with COPD
and asthma [25].
Furthermore, we observed a bimodal lag distribution of
peak effects of NO2 and TSP in all subgroups, although
there was variation in timing and magnitude by condition.
For the COPD subgroup, the development of respiratory
symptoms leading to a doctor visit on the second or third
day after exposure to NO2 may reflect a more rapid mech-
anism of airway irritation in individuals with more severe
obstruction, or with presence of other susceptibility factors
including older age and co-morbidities. The second wave
of doctor visits on 9–10 days following exposure may be
due to delayed or slower effects of a similar mechanism in
milder cases of obstruction but might also be an artefact.
The presence of such a second peak would need to be con-
firmed with other data.
This study has multiple strengths and limitations that are
inherent to its design. The subjects of the SAPALDIA diary
study participated one to two years earlier in the baseline
survey of SAPALDIA, which included information on spir-
ometry and methacholine challenge testing, and respiratory
symptoms. Many of the diary study participants were se-
lected on the basis of presenting with respiratory symptoms
or poor lung function at the baseline survey, which enabled
us to make comparisons between subgroups [11, 12].
However, misclassification of subgroup is a possibility,
particularly for COPD. While the prevalence of COPD in
the younger age demographic of the general population is
rare, 9 of the 54 participants (16.7%) in the COPD sub-
group were less than 40 years of age, although the higher
Table 2: Distribution of 24-hr mean concentrations of NO2 (µg/m
3) for case and control-days from all participants (n = 457).
Lag Case/Control-days* Mean SD 10th 25th 50th 75th 90th
Case 34.4 22.2 8.5 15.4 31.1 49.7 63.3
Control 33.4 20.1 8.4 15.8 31.8 48.5 59.1
0
Difference 0.9 13.9 –14.2 –5.6 0.5 7.2 17.1
Case 33.0 22.3 7.9 14.8 29.3 47.3 62.2
Control 32.4 19.8 8.1 14.7 30.0 46.3 58.3
1
Difference 0.6 14 –14.6 –6.1 0.6 7.2 17
Case 32.8 22.1 7.5 14.1 30.1 46.8 63.4
Control 32.2 19.7 7.6 14.7 30.4 46.4 57.3
2
Difference 0.7 13.9 –14.2 –5.4 0.6 7.6 17.1
Case 33.3 22.0 8.2 15.4 30.3 47.1 62.3
Control 32.7 19.5 7.9 15.2 31.8 46.9 58.2
3
Difference 0.8 13.5 –14.9 –5.5 0.4 7.2 15.5
Case 33.6 22.5 8.2 15.4 31.1 47.2 61.8
Control 32.7 19.3 8.3 15.9 32.5 46.1 59.3
4
Difference 1.0 13.6 –14.7 –4.9 0.8 6.7 16.6
Case 33.7 22.5 7.9 15.3 30.7 47.1 61.9
Control 33.0 19.8 8.2 15.1 31.9 47.3 59.3
5
Difference 0.7 13.6 –14.1 –5.5 0.2 6.8 16.3
Case 34.5 23.1 8.1 15.3 31.6 48.4 63.0
Control 34.0 20.3 8.4 16.0 33.8 48.8 60.6
6
Difference 0.6 13.5 –14.5 –6.0 -0.2 6.8 15.4
Case 34.1 22.4 8.3 15.2 31.5 47.8 62.1
Control 34.0 20.2 8.5 16.3 33.0 49.0 60.1
7
Difference 0.0 13.3 –15.0 –6.3 –0.3 6.6 15.8
Case 32.5 21.7 8.0 14.4 30.0 46.2 59.9
Control 32.7 19.9 7.9 15.1 31.0 47.6 60.3
8
Difference –0.2 14.1 –16.2 –6.8 –0.1 6.2 15.5
Case 32.3 21.6 7.4 14.5 29.2 45.8 59.4
Control 32.7 19.7 7.6 15.1 32.1 47.6 57.2
9
Difference –0.3 14.2 –16.3 –6.5 –0.2 6.1 15.1
Case 33.0 21.7 7.8 14.7 30.3 47.6 62.0
Control 33.2 19.8 8.2 15.9 32.5 47.1 58.8
10
Difference –0.3 13.9 –16.7 –6.3 0.0 6.0 16.0
Case 33.0 21.2 8.2 15.1 31.3 46.9 60.8
Control 33.4 20.2 8.5 15.9 33.2 47.2 59.2
11
Difference –0.5 13.6 –17.2 –6.6 –0.3 6.2 15.8
Case 33.0 21.3 8.0 14.7 31.2 47.1 59.9
Control 33.6 20.4 8.1 15.7 33.2 47.4 60.7
12
Difference –0.5 13.1 –16.3 –6.6 –0.3 5.6 14.6
Case 34.3 22.1 8.0 15.9 32.1 49.9 62.2
Control 34.3 20.5 8.5 16.1 34.0 48.5 60.7
13
Difference 0.0 13.0 –15.9 –6.9 –0.2 6.1 16.0
* There were 914 case-days and 2,362 control days with complete information on NO2 concentration and other covariates. The difference in NO2 concentration was
estimated from concentration measured on case-day minus the mean concentration measured on control-days occurring in the diary period.
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prevalence may reflect the selection of those who reported
doctor visits. Bronchodilator tests were also not performed
in the SAPALDIA baseline survey, so it was not possible to
adhere to the more strict definition of COPD. Instead, val-
idated questions for history of physician diagnosed asthma,
current asthma, and asthma medication use in combination
with lung function testing were used to minimise the inclu-
sion of participants with potential asthma in the COPD sub-
group. Furthermore, lag structures were similar between
asthmatics who reported or didn’t report asthma medica-
tion use in the 1991 baseline survey (data not shown); if
unrecognised and untreated asthmatics were excluded from
the COPD subgroup, the lagged effect patterns between the
COPD and asthma subgroups would be likely to differ even
more. Finally, to ensure accurate classification of healthy
participants, normal bronchial reactivity tests were re-
quired in addition to absence of asthma, bronchitis symp-
toms, and airflow obstruction. The distinct patterns of time-
related effects of NO2 effects observed between the asthma,
COPD, and healthy subgroups suggest that misclassifica-
tion is likely to be minimal.
The case-crossover analysis, in which the same participant
was both a case and a control, prevented confounding by
gender, age, smoking status and other individual factors
that do not vary within time strata. However, there may
be unmeasured confounding by time-varying factors, in-
cluding daily medication use, which was not available in
this analysis. Moderate prevalence of asthma medication
or inhalation steroids, according to data collected at the
baseline survey of SAPALDIA, was only observed in the
asthma subgroup. As described in the previous paragraph,
lag structures were also similar between treated and un-
treated participants in the asthma subgroup. Thus, unmeas-
ured confounding by daily medication use in asthmatic par-
ticipants may be rather minimal.
While referent time periods are individually matched to
case time periods in case-crossover studies, there are sever-
al different strategies to select referent periods, and the risk
estimates may vary by selection strategy [26, 27]. Based
on review of this literature, we chose our referent periods
using a time-stratified design, in which control and case-
days were matched by weekday within the diary period,
thus providing sufficient control for time trend biases in-
cluding seasonal trends [27].
The observed associations between daily levels of NO2 and
TSP and reported doctor visits were statistically signific-
ant at specific lags, but were mostly of smaller magnitude
with confidence intervals indicating wide variation. The
CLR models were adjusted for time-varying factors includ-
ing weekly flu prevalence at the regional level and com-
plex combinations of meteorological variables. Effect es-
timates of similar magnitude were also observed in CLR
models that were unadjusted for meteorological covariates
(data not shown). Furthermore, these models were strati-
fied by presence of chronic respiratory disease, gender, and
smoking to account for the hypothesised heterogeneity of
effects between subgroups.
The assignment of daily exposure was also based on fixed
site monitors that have rather limited precision to indicate
exposure of a particular participant on a given day, so there
is potential for exposure misclassification of NO2 and TSP.
However, relevant to TSP, the spatial homogeneity of par-
ticulate concentrations was demonstrated to be quite high
in one of the regions for this study [28]. Finally, other
potential causal components, including ultrafine particles,
were not addressed and may explain the observed effects in
this study. Ambient NO2 was and still is a proxy for com-
bustion, and nearly 20 years ago, it was strongly related to
traffic; while ultrafine particle data was not collected in this
study, we may consider NO2 a proxy of traffic related PM.
Conclusions
In summary, an increase in exposure to NO2 and TSP was
associated with a visit to the doctor for a few days follow-
ing exposure. Respiratory problems leading to a doctor vis-
it may have a faster dynamic in individuals with underlying
COPD.
Table 3: Adjusted OR's* for doctor’s visit for respiratory symptoms per 10 µg/m3 increase in NO2.
Asthma Bronchitis COPD Healthy
N doctor visits 167 407 150 207
OR** 95%CI** OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.019 0.849 1.223 1.116 1.001 1.244 1.098 0.908 1.328 0.978 0.832 1.148
Lag 1 0.953 0.878 1.036 1.047 0.996 1.101 1.134 1.029 1.250 0.924 0.852 1.001
Lag 2 0.892 0.789 1.009 0.983 0.913 1.059 1.171 1.017 1.348 0.873 0.769 0.990
Lag 3 0.937 0.828 1.060 0.981 0.914 1.053 1.146 1.002 1.311 0.919 0.822 1.027
Lag 4 1.067 0.966 1.178 1.033 0.970 1.099 1.073 0.969 1.188 1.027 0.941 1.122
Lag 5 1.152 1.024 1.295 1.071 0.992 1.156 1.020 0.896 1.160 1.075 0.959 1.205
Lag 6 1.135 1.023 1.258 1.067 1.004 1.134 1.006 0.896 1.131 1.035 0.945 1.134
Lag 7 1.048 0.945 1.162 1.027 0.967 1.091 1.028 0.929 1.138 0.965 0.883 1.055
Lag 8 0.962 0.858 1.079 0.975 0.905 1.051 1.064 0.954 1.188 0.933 0.835 1.043
Lag 9 0.930 0.853 1.013 0.939 0.884 0.997 1.087 0.988 1.196 0.978 0.898 1.066
Lag 10 0.970 0.868 1.085 0.934 0.871 1.002 1.070 0.953 1.200 1.085 0.975 1.208
Lag 11 1.051 0.932 1.185 0.959 0.889 1.035 1.004 0.893 1.128 1.107 0.983 1.248
Lag 12 1.119 1.036 1.208 0.994 0.948 1.042 0.921 0.838 1.012 0.996 0.928 1.069
Lag 13 1.191 1.007 1.409 1.029 0.930 1.139 0.845 0.700 1.021 0.896 0.768 1.046
* As estimated in conditional logistic regression at different lags and adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6
days up to 2 degrees of freedom, and average T, RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
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Appendix: Supplementary file
Supplementary file: Table 1
Characteristics* of subjects with asthma and COPD who report or did not doctor visits for respiratory symptoms in the SAPALDIA diary study.
Asthma COPD
Did not report doctor visit Reported doctor visit Did not report doctor visit Reported doctor visit
Number of subjects 251 78 296 54
n (%)** n (%) n (%) n (%)
Sex
Male 124 (49.4) 31 (39.7) 192 (64.9) 29 (53.7)
Female 127 (50.6) 47 (60.3) 104 (35.1) 25 (46.3)
Age
<35 72 (28.7) 17 (21.8) 19 (6.4) 7 (13.0)
35–45 62 (24.7) 24 (30.8) 77 (26.0) 10 (18.5)
>45 117 (46.6) 37 (47.4) 200 (67.6) 37 (68.5)
mean (SD) 42.3 (11.7) 43.6 (10.1) 49.0 (9.0) 48.2 (9.9)
Bronchitis symptoms
Yes 92 (36.7) 40 (51.3) 107 (36.2) 23 (42.6)
No 159 (63.4) 38 (48.7) 189 (63.9) 31 (57.4)
Smoking status
Current smoker 60 (23.9) 14 (17.3) 104 (35.1) 24 (46.0)
Former or never smoker 191 (76.1) 64 (82.7) 192 (64.9) 30 (54.0)
Current asthma medication use
Yes 72 (28.7) 35 (44.9) 0 0
No 179 (71.3) 43 (55.1) 0 0
Lung function
Percent predicted FEV1, mean (SD) 97.8 (18.3) 88.7 (21.9) 95.2 (16.1) 91.9 (16.2)
* Characteristics summarised from the baseline survey of SAPALDIA (1991)
** Expressed as n (%) unless otherwise noted
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Supplementary file: Table 2
Adjusted OR's* for doctor’s visit for respiratory symptoms per 10 µg/m3 increase in NO2 after stratification by smoking status.
Current smokers
Asthma Bronchitis COPD Healthy
N doctor visits 44 196 75 25
OR** 95%CI** OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.207 0.743 1.962 1.110 0.943 1.307 1.284 0.881 1.872
Lag 1 1.003 0.828 1.214 1.066 0.985 1.154 1.371 1.064 1.767
Lag 2 0.833 0.635 1.093 1.024 0.909 1.154 1.464 1.064 2.013
Lag 3 0.834 0.615 1.130 1.026 0.917 1.148 1.248 0.947 1.646
Lag 4 1.010 0.716 1.424 1.057 0.957 1.167 0.964 0.776 1.197
Lag 5 1.218 0.827 1.793 1.065 0.943 1.203 0.892 0.689 1.155
Lag 6 1.321 0.978 1.784 1.038 0.943 1.143 1.022 0.806 1.295
Lag 7 1.258 0.930 1.701 0.991 0.906 1.085 1.283 0.993 1.658
Lag 8 1.086 0.766 1.539 0.951 0.848 1.067 1.482 1.101 1.995
Lag 9 0.914 0.727 1.149 0.938 0.851 1.033 1.379 1.082 1.759
Lag 10 0.824 0.614 1.105 0.956 0.859 1.065 1.040 0.811 1.334
Lag 11 0.877 0.607 1.267 0.987 0.881 1.105 0.810 0.610 1.076
Lag 12 1.046 0.882 1.240 1.006 0.934 1.083 0.753 0.583 0.971
Lag 13 1.247 0.906 1.717 1.025 0.880 1.194 0.699 0.460 1.062
N/A
Former or never smokers
Asthma Bronchitis COPD Healthy
N doctor visits 123 210 75 182
OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.060 0.846 1.327 1.146 0.975 1.346 1.219 0.865 1.717 1.005 0.836 1.209
Lag 1 0.954 0.855 1.064 1.024 0.949 1.106 1.012 0.861 1.190 0.937 0.855 1.026
Lag 2 0.859 0.730 1.011 0.916 0.821 1.021 0.840 0.642 1.099 0.873 0.758 1.004
Lag 3 0.901 0.768 1.056 0.917 0.827 1.017 0.855 0.659 1.109 0.920 0.812 1.043
Lag 4 1.055 0.939 1.185 1.017 0.932 1.109 1.011 0.852 1.199 1.046 0.949 1.154
Lag 5 1.159 1.009 1.333 1.106 0.993 1.232 1.112 0.898 1.378 1.115 0.980 1.269
Lag 6 1.142 0.999 1.304 1.124 1.027 1.229 1.081 0.893 1.309 1.087 0.976 1.210
Lag 7 1.044 0.906 1.202 1.070 0.980 1.169 0.979 0.832 1.151 1.015 0.917 1.124
Lag 8 0.955 0.822 1.109 0.989 0.891 1.098 0.908 0.758 1.088 0.974 0.861 1.102
Lag 9 0.937 0.841 1.044 0.928 0.856 1.006 0.930 0.797 1.084 1.006 0.913 1.110
Lag 10 1.006 0.873 1.160 0.915 0.828 1.010 1.039 0.857 1.259 1.095 0.968 1.238
Lag 11 1.098 0.944 1.277 0.951 0.853 1.060 1.082 0.882 1.327 1.091 0.954 1.247
Lag 12 1.143 1.031 1.266 1.005 0.939 1.075 0.982 0.828 1.164 0.956 0.880 1.039
Lag 13 1.189 0.948 1.490 1.062 0.918 1.229 0.890 0.636 1.247 0.838 0.701 1.003
* As estimated in conditional logistic regression per 10 µg/m3 increase in NO2 at different lags and adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T
2,
RH2, and T*RH from lag 0-6 days up to 2 degrees of freedom, and average T, RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
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Supplementary file: Table 3
Adjusted OR's* for doctor’s visit for respiratory symptoms per 10 µg/m3 increase in NO2 after stratification by gender.
Males
Asthma Bronchitis COPD Healthy
N doctor visits 81 168 93 59
OR** 95%CI** OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.106 0.803 1.524 1.272 1.055 1.535 1.053 0.824 1.347 1.051 0.646 1.710
Lag 1 0.985 0.860 1.128 1.099 1.008 1.197 1.129 0.987 1.292 0.792 0.589 1.064
Lag 2 0.878 0.714 1.079 0.949 0.826 1.090 1.210 1.003 1.459 0.597 0.374 0.954
Lag 3 0.957 0.771 1.187 0.986 0.867 1.122 1.247 1.041 1.494 0.740 0.517 1.057
Lag 4 1.166 0.972 1.399 1.164 1.041 1.302 1.209 1.037 1.410 1.197 0.936 1.530
Lag 5 1.252 1.016 1.541 1.263 1.096 1.456 1.135 0.942 1.368 1.410 0.998 1.990
Lag 6 1.139 0.964 1.347 1.192 1.070 1.329 1.065 0.903 1.256 1.124 0.903 1.398
Lag 7 0.960 0.821 1.123 1.030 0.934 1.135 1.025 0.894 1.176 0.765 0.593 0.986
Lag 8 0.855 0.710 1.029 0.894 0.783 1.021 1.026 0.885 1.188 0.620 0.425 0.906
Lag 9 0.891 0.774 1.027 0.852 0.760 0.954 1.058 0.925 1.210 0.754 0.582 0.979
Lag 10 1.079 0.896 1.299 0.909 0.805 1.028 1.086 0.928 1.270 1.270 0.879 1.833
Lag 11 1.247 1.003 1.551 0.985 0.863 1.123 1.032 0.887 1.200 1.633 1.053 2.532
Lag 12 1.241 1.061 1.450 0.996 0.914 1.086 0.912 0.799 1.040 1.272 0.995 1.625
Lag 13 1.234 0.933 1.632 1.008 0.845 1.204 0.806 0.616 1.054 0.990 0.563 1.742
Females
Asthma Bronchitis COPD Healthy
N doctor visits 86 239 57 148
OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Lag 0 0.913 0.699 1.191 1.038 0.894 1.206 2.330 0.989 5.486 0.966 0.795 1.172
Lag 1 0.902 0.788 1.032 1.021 0.952 1.096 1.958 1.215 3.156 0.933 0.845 1.031
Lag 2 0.891 0.738 1.075 1.005 0.911 1.108 1.646 0.947 2.864 0.902 0.775 1.049
Lag 3 0.957 0.797 1.149 0.986 0.896 1.086 1.307 0.814 2.098 0.935 0.819 1.068
Lag 4 1.091 0.941 1.264 0.977 0.899 1.061 1.051 0.806 1.370 1.018 0.916 1.130
Lag 5 1.191 1.002 1.415 0.982 0.890 1.083 0.948 0.638 1.408 1.071 0.932 1.231
Lag 6 1.198 1.023 1.403 0.995 0.917 1.080 0.970 0.689 1.366 1.069 0.954 1.199
Lag 7 1.122 0.949 1.326 1.004 0.923 1.091 1.074 0.801 1.441 1.034 0.929 1.150
Lag 8 1.018 0.851 1.217 0.998 0.904 1.101 1.194 0.823 1.734 1.002 0.878 1.143
Lag 9 0.941 0.826 1.072 0.974 0.901 1.053 1.242 0.917 1.682 1.000 0.899 1.112
Lag 10 0.928 0.775 1.110 0.945 0.859 1.040 1.168 0.832 1.639 1.024 0.902 1.161
Lag 11 0.994 0.825 1.198 0.942 0.852 1.043 1.028 0.694 1.522 1.012 0.881 1.164
Lag 12 1.107 0.995 1.231 0.970 0.909 1.036 0.907 0.687 1.197 0.947 0.869 1.033
Lag 13 1.233 0.952 1.598 0.999 0.868 1.149 0.800 0.466 1.374 0.886 0.742 1.059
* As estimated in conditional logistic regression per 10 µg/m3 increase in NO2 at different lags and adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T
2,
RH2, and T*RH from lag 0-6 days up to 2 degrees of freedom, and average T, RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
Original article Swiss Med Wkly. 2012;142:w13681
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Supplementary file: Table 4
Distribution of 24-mean concentrations of TSP (µg/m3) for case and control-days.
Lag Case/Control* Mean SD 10th 25th 50th 75th 90th
Case-days 35.7 27.2 10.9 17.0 27.3 45.3 72.00
Control-days 33.9 21.5 12.7 17.7 12.7 44.5 62.0
Case-days 34.3 26.0 10.0 15.6 26.4 45.0 70.01
Control-days 33.4 20.3 12.3 18.5 28.5 43.8 62.7
Case-days 34.2 26.0 9.8 14.8 26.0 47.0 73.02
Control-days 32.7 20.0 12.3 17.5 28.0 42.4 63.0
Case-days 34.9 26.7 10.4 15.8 25.9 48.0 72.03
Control-days 33.1 20.0 12.0 17.3 28.7 44.1 61.5
Case-days 35.4 27.1 10.0 16.2 27.0 48.0 72.04
Control-days 33.1 20.1 12.0 17.3 28.5 44.3 62.7
Case-days 35.7 27.6 9.8 15.6 28.0 46.2 74.15
Control-days 33.9 21.0 12.2 17.3 29.0 46.0 65.6
Case-days 36.2 28.4 10.4 16.0 28.0 47.0 75.06
Control-days 34.7 21.2 12.5 18.7 30.4 45.0 63.8
Case-days 35.3 28.1 10.0 16.0 27.0 45.0 72.07
Control-days 34.9 21.5 12.5 18.7 31.0 45.3 64.0
Case-days 33.9 25.9 9.4 16.0 26.5 45.0 68.08
Control-days 33.8 20.5 12.5 18.1 29.4 44.8 62.3
Case-days 33.4 25.2 9.8 15.6 26.0 44.0 66.09
Control-days 33.7 20.7 12.5 17.9 28.5 46.0 61.0
Case-days 33.9 25.4 9.7 15.4 27.2 45.8 67.010
Control-days 34.0 21.1 12.5 17.9 28.6 46.0 64.5
Case-days 34.0 25.1 10.0 15.0 27.0 46.0 69.211
Control-days 34.5 21.0 13.0 18.1 28.3 46.1 64.3
Case-days 33.9 26.8 10.0 15.0 26.2 42.9 70.012
Control-days 35.2 21.7 12.8 18.7 29.3 47.3 65.3
Case-days 34.8 27.1 9.8 15.5 27.0 45.0 69.713
Control-days 35.7 22.0 12.7 19.1 30.3 47.7 66.0
* There were 892 case-days and 2,230 control days with complete information on TSP concentration and other covariates.
Supplementary file: Table 5
Adjusted OR's* for doctor's visit for respiratory symptoms per 10 µg/m3 increase in TSP at separate lags in major subcategories of participants as estimated in conditional
logistic regression.
All subjects
Asthma diagnosis Bronchitis COPD Healthy
n visits 170 414 148 181
OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Lag 0 0.977 0.875 1.091 1.016 0.957 1.079 1.001 0.894 1.120 0.966 0.885 1.054
Lag 1 0.979 0.930 1.031 1.013 0.984 1.042 1.032 0.976 1.092 0.966 0.930 1.003
Lag 2 0.981 0.912 1.057 1.009 0.965 1.055 1.065 0.984 1.152 0.966 0.901 1.035
Lag 3 1.020 0.947 1.099 1.011 0.970 1.054 1.051 0.978 1.131 0.991 0.928 1.059
Lag 4 1.068 1.003 1.137 1.013 0.976 1.052 1.006 0.944 1.072 1.025 0.974 1.079
Lag 5 1.073 1.002 1.150 1.009 0.964 1.055 0.981 0.905 1.063 1.033 0.970 1.101
Lag 6 1.036 0.981 1.093 0.999 0.965 1.035 0.986 0.924 1.052 1.015 0.964 1.068
Lag 7 0.988 0.932 1.047 0.991 0.956 1.027 1.013 0.959 1.070 0.990 0.944 1.039
Lag 8 0.965 0.899 1.035 0.989 0.945 1.035 1.040 0.972 1.111 0.983 0.925 1.045
Lag 9 0.985 0.932 1.041 0.995 0.960 1.032 1.045 0.985 1.108 1.007 0.954 1.062
Lag 10 1.037 0.967 1.113 1.004 0.962 1.048 1.022 0.947 1.102 1.051 0.989 1.117
Lag 11 1.049 0.974 1.130 0.997 0.952 1.045 0.990 0.917 1.068 1.065 1.001 1.133
Lag 12 0.996 0.952 1.042 0.974 0.946 1.002 0.969 0.920 1.021 1.031 0.990 1.074
Lag 13 0.946 0.855 1.046 0.950 0.895 1.009 0.949 0.843 1.068 0.999 0.914 1.091
* All models were adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days up to 2 degrees of freedom, and average T,
RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
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Supplementary file: Table 6
Adjusted OR's* for doctor's visit per 10 µg/m3 increase in TSP at separate lags in major subcategories of participants after stratification by smoking status as estimated in
conditional logistic regression.
Current smokers Former or never smokers
Asthma Bronchitis COPD Asthma Bronchitis COPD Healthy
n visits 48 198 78 122 215 70 153
OR** 95%CI** OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.062 0.749 1.506 1.030 0.941 1.126 1.043 0.871 1.250 0.974 0.853 1.111 1.003 0.916 1.098 1.002 0.808 1.242 0.910 0.808 1.024
Lag 1 0.934 0.787 1.109 1.025 0.980 1.073 1.089 0.984 1.205 0.998 0.937 1.062 1.003 0.959 1.048 0.981 0.880 1.093 0.944 0.899 0.991
Lag 2 0.821 0.658 1.025 1.021 0.953 1.093 1.137 0.996 1.298 1.022 0.931 1.122 1.002 0.937 1.073 0.960 0.813 1.133 0.979 0.899 1.066
Lag 3 0.847 0.680 1.056 1.017 0.955 1.082 1.071 0.956 1.200 1.050 0.955 1.154 1.012 0.950 1.078 0.967 0.826 1.133 1.022 0.940 1.110
Lag 4 0.993 0.799 1.234 1.013 0.956 1.074 0.953 0.860 1.056 1.058 0.981 1.141 1.021 0.967 1.077 1.004 0.880 1.147 1.051 0.986 1.119
Lag 5 1.113 0.876 1.416 1.009 0.940 1.082 0.906 0.789 1.040 1.036 0.954 1.125 1.016 0.951 1.084 1.043 0.889 1.224 1.049 0.970 1.135
Lag 6 1.127 0.946 1.343 1.001 0.950 1.054 0.939 0.838 1.052 0.999 0.933 1.069 1.002 0.951 1.056 1.069 0.939 1.217 1.026 0.964 1.092
Lag 7 1.053 0.870 1.275 0.989 0.938 1.042 1.018 0.930 1.115 0.973 0.902 1.049 0.995 0.942 1.050 1.079 0.967 1.203 1.003 0.945 1.064
Lag 8 0.965 0.753 1.238 0.973 0.909 1.042 1.081 0.970 1.205 0.978 0.894 1.070 1.004 0.940 1.073 1.078 0.943 1.232 0.998 0.924 1.079
Lag 9 0.922 0.759 1.121 0.958 0.906 1.012 1.068 0.970 1.177 1.019 0.951 1.092 1.032 0.979 1.088 1.075 0.944 1.223 1.022 0.955 1.094
Lag 10 0.940 0.762 1.159 0.951 0.889 1.017 0.985 0.875 1.110 1.073 0.989 1.165 1.059 0.994 1.128 1.076 0.915 1.266 1.059 0.981 1.143
Lag 11 0.967 0.769 1.217 0.964 0.897 1.036 0.934 0.831 1.051 1.062 0.973 1.160 1.032 0.964 1.106 1.084 0.923 1.273 1.059 0.980 1.145
Lag 12 0.957 0.836 1.095 0.994 0.955 1.036 0.956 0.876 1.044 0.982 0.929 1.039 0.955 0.912 1.001 1.092 0.959 1.244 1.012 0.966 1.061
Lag 13 0.946 0.702 1.275 1.026 0.938 1.122 0.979 0.805 1.190 0.908 0.806 1.023 0.884 0.802 0.974 1.101 0.853 1.421 0.968 0.870 1.076
* All models were adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days up to 2 degrees of freedom, and average T,
RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
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Supplementary file: Table 7
Adjusted OR's* for doctor's visit per 10 µg/m3 increase in TSP at separate lags in major subcategories of participants after stratification by gender as estimated in
conditional logistic regression.
Males
Asthma Bronchitis COPD Healthy
n visits 81 173 92 42
OR** 95%CI** OR 95%CI OR 95%CI OR 95%CI
Lag 0 1.140 0.929 1.399 1.014 0.896 1.147 1.016 0.882 1.170 0.764 0.486 1.202
Lag 1 1.052 0.956 1.159 1.020 0.961 1.082 1.032 0.960 1.109 0.896 0.753 1.067
Lag 2 0.971 0.850 1.111 1.025 0.951 1.105 1.048 0.949 1.158 1.051 0.715 1.545
Lag 3 0.986 0.864 1.126 1.044 0.971 1.123 1.057 0.964 1.158 1.331 0.885 2.002
Lag 4 1.061 0.944 1.193 1.056 0.988 1.129 1.048 0.965 1.138 1.505 1.089 2.080
Lag 5 1.087 0.946 1.250 1.041 0.962 1.126 1.028 0.927 1.139 1.303 0.932 1.824
Lag 6 1.043 0.936 1.161 1.005 0.946 1.066 1.008 0.929 1.094 0.942 0.728 1.219
Lag 7 0.972 0.883 1.070 0.969 0.916 1.025 1.001 0.934 1.073 0.698 0.541 0.901
Lag 8 0.931 0.822 1.056 0.953 0.885 1.026 1.013 0.932 1.102 0.653 0.477 0.894
Lag 9 0.954 0.859 1.060 0.966 0.909 1.027 1.041 0.966 1.121 0.847 0.678 1.059
Lag 10 1.030 0.926 1.145 0.996 0.930 1.068 1.060 0.960 1.172 1.328 1.031 1.712
Lag 11 1.054 0.940 1.183 0.995 0.926 1.070 1.025 0.931 1.128 1.544 1.139 2.093
Lag 12 0.986 0.905 1.074 0.952 0.904 1.003 0.943 0.882 1.009 1.175 0.945 1.461
Lag 13 0.922 0.773 1.099 0.910 0.814 1.019 0.869 0.739 1.020 0.894 0.572 1.400
Females
Asthma Bronchitis COPD Healthy
n visits 89 241 56 139
OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Lag 0 0.947 0.803 1.116 1.041 0.959 1.130 1.038 0.588 1.832 0.983 0.868 1.114
Lag 1 0.971 0.900 1.047 1.017 0.976 1.061 1.315 0.943 1.833 0.973 0.919 1.030
Lag 2 0.995 0.887 1.116 0.994 0.935 1.058 1.667 1.031 2.694 0.962 0.879 1.054
Lag 3 1.029 0.918 1.154 0.985 0.930 1.044 1.350 0.948 1.923 0.975 0.893 1.066
Lag 4 1.065 0.966 1.175 0.989 0.939 1.043 0.870 0.668 1.133 1.012 0.949 1.080
Lag 5 1.084 0.971 1.210 0.996 0.937 1.059 0.761 0.519 1.116 1.047 0.967 1.133
Lag 6 1.078 0.981 1.185 1.001 0.954 1.050 0.968 0.754 1.242 1.063 0.993 1.139
Lag 7 1.052 0.948 1.169 1.004 0.954 1.056 1.443 1.027 2.027 1.057 0.993 1.125
Lag 8 1.018 0.906 1.143 1.008 0.946 1.073 1.850 1.081 3.167 1.032 0.958 1.111
Lag 9 0.987 0.908 1.073 1.012 0.964 1.063 1.640 1.051 2.558 1.002 0.938 1.070
Lag 10 0.972 0.858 1.101 1.015 0.956 1.077 1.067 0.815 1.397 0.982 0.907 1.064
Lag 11 0.982 0.860 1.122 1.005 0.940 1.073 0.861 0.632 1.172 0.992 0.916 1.074
Lag 12 1.007 0.941 1.078 0.982 0.944 1.022 1.073 0.871 1.321 1.023 0.976 1.073
Lag 13 1.032 0.877 1.215 0.960 0.887 1.040 1.337 0.848 2.107 1.056 0.949 1.174
* All models were adjusted for flu prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days up to 2 degrees of freedom, and average T,
RH, AP, and T2 from lag 7–13 days.
** Bold font indicates p-values <0.05.
Supplementary file: Figure 1
Adjusted OR’s for doctor visits for respiratory symptoms per 10 µg/m3 increase in TSP at separate lags in subjects with asthma (A), chronic
bronchitis (B), COPD (C), and subjects who are healthy (D) as estimated in conditional logistic regression. All models were adjusted for flu
prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days up to 2 degrees of freedom, and average T, RH, AP,
and T2 from lag 7–13 days.
Original article Swiss Med Wkly. 2012;142:w13681
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 15 of 17
Figures (large format)
Figure 1
Adjusted OR’s* for doctor’s visit for respiratory symptoms per 10 µg/m3 increase in NO2.
* As estimated in separate conditional logistic regression models in the asthma, chronic bronchitis, COPD, and healthy subgroups, and adjusted
for flu prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days at up to 2 degrees of freedom, and average T,
RH, AP, and T2 from lag 7–13 days.
Figure 2
Average percent change* in number of doctor visits following a 10 µg/m3 increase in NO2 concentration.
* For each subgroup, areas under the curve were estimated from adjusted conditional logistic regression models to approximate the average
percent change in number of doctor visits over 1 and 2 week periods following a 10 µg/m3 increase in exposure to NO2 concentration on a given
day.
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Supplementary file: Figure 1
Adjusted OR’s for doctor visits for respiratory symptoms per 10 µg/m3 increase in TSP at separate lags in subjects with asthma (A), chronic
bronchitis (B), COPD (C), and subjects who are healthy (D) as estimated in conditional logistic regression. All models were adjusted for flu
prevalence, polynomial distributed lags of T, RH, AP, T2, RH2, and T*RH from lag 0–6 days up to 2 degrees of freedom, and average T, RH, AP,
and T2 from lag 7–13 days.
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